Q-omics provides the consensus-scored HOXA2 profile across patient tissues and cancer cell-line models. HOXA2 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, HOXA2 is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, HOXA2 RNA expression shows 14,954 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, KICH, and THYM as cancer lineages where HOXA2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HOXA2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HOXA2 survival associations across molecular data types. HOXA2 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HOXA2 RNA expression–survival associations across cancer types. High HOXA2 expression shows unfavorable associations in KIRC, UCEC, CESC, LGG and ACC, but favorable associations in BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for HOXA2 RNA expression.
This table summarizes HOXA2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for HOXA2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HOXA2 shows lower tumor expression in KICH, LUSC, KIRC, LUAD, THCA and BRCA. The KICH box plot shows higher HOXA2 RNA expression in normal versus tumor tissue (log2 FC = −1.646, t-test p < 0.001).
This table shows molecular features associated with HOXA2 in patient tissues and cancer cell lines. In patient samples, HOXA2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, HOXA2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
